Immunic, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 93.61 million compared to USD 120.41 million a year ago. Basic loss per share from continuing operations was USD 2.11 compared to USD 3.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | +2.42% | -7.30% | -15.33% |
08/05 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
08/05 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.33% | 114M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023